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Aim: To investigate the influences of bacterial or viral pathogen burden in the relationship
of high sensitivity C-reactive protein (hs-CRP) and the metabolic syndrome in a population-
based study.
Methods: Data from 1754 men and women aged 25 years, from the Persian Gulf Healthy
Heart Studywere analyzed. The definition of themetabolic syndrome according to the Adult
Treatment Panel III was used. Sera were analyzed for IgG antibodies to Chlamydia pneumo-
niae, Herpes simplex virus type 1, Helicobacter pylori and cytomegalovirus using ELISA.
Measurement of CRP by a high-sensitivity CRP assay was done.
Results: The subjects with the metabolic syndrome had a higher geometric mean of CRP
levels than the normal persons (p < 0.0001). A linear relationship between an increase in the
number of metabolic syndrome components and CRP concentrations was observed ( p for
trend < 0.0001). In multiple logistic regression models, hs-CRP showed significant associa-
tions with the metabolic syndrome after controlling for cardiovascular risk factors and
infectious burden divided into 2, 3 and 4 pathogens [OR = 2.06, CI (1.32–3.21), p = 0.001;
OR = 1.75, CI (1.26–2.42), p = 0. 001; OR = 2.12, CI (1.46–3.08), p < 0.0001; respectively].
Conclusion: There was a strong association between inflammation and the metabolic syn-
drome independent to viral and bacterial infectious burden.
# 2009 Elsevier Ireland Ltd. All rights reserved.
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Metabolic syndrome means a clustering of anthropometric,
physiologic, and biochemical abnormalities, it is a significant
contributor tocardiovascularmorbidityandmortality [1–3]. The
National Cholesterol Education Program (NCEP) Adult Treat-
mentPanel III introducedadefinition to identify individualwith
high risk for cardiovascular disease and/or type 2 diabetes [4].* Corresponding author at: The Persian Gulf Tropical Medicine Resea
Iran Postal Code 7514763448, Iran. Tel.: +98 771 2541827; fax: +98 771
E-mail addresses: inabipour@gmail.com, inabim@yahoo.com (I. N
0168-8227/$ – see front matter # 2009 Elsevier Ireland Ltd. All rights
doi:10.1016/j.diabres.2009.03.010The role of inflammation in the development of insulin
resistance, the metabolic syndrome and all stages of the
atherosclerosis was investigated [5–8]. There is growing
evidence to suggest chronic, low-grade and subclinical
internal inflammation in the etiopathogenesis of the meta-
bolic syndrome [9]. Measurement of the concentration of C-
reactive protein (CRP), an acute phase reactant, has been used
in the diagnosis and monitoring of chronic, low-graderch Center, Boostan 19 Alley, Imam Khomeini Street, Bushehr, I.R.
2541828.
abipour).
reserved.
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6 and TNF-alpha [10].
In epidemiological studies, an increased level of CRP has
been associated with the metabolic syndrome and its
components, among children, youth and adults [11–17].
Some prospective epidemiological evidence linking inflam-
mation with the metabolic syndrome has been accumulated
[18–20].
Based on these evidences, some investigators have
suggested that hs-CRP should be added in the definition of
the metabolic syndrome and for the creation of an hs-CRP
modified coronary heart disease risk score useful for global
risk prediction in both men and women [21–22].
From another view, viral and bacterial infections induce
production of various cytokines and can amplify inflamma-
tory mediators, resulting in insulin resistance, the central
pathological mechanism of the metabolic syndrome [23].
Therefore, it has been suggested that inflammation is behind
the link between pathogen burden and insulin resistance [24].
In fact, there are limited studies about the association of
chronic subclinical infections and the development of chronic
insulin resistance and the metabolic syndrome or its compo-
nents [24–27].
Recently, we have shown that the metabolic syndrome,
which occurs very frequently in our general population, had a
significant association with prior infection with Chlamydia
pneumoniae, Helicobacter pylori, cytomegalovirus and herpes
simplex virus type 1 [27]. However, whether the presence of
chronic subclinical infectionswith bacterial or viral pathogens
influences the relationship between hs-CRP and themetabolic
syndrome has not been well established yet.
We therefore investigated association of the metabolic
syndrome and increased level of hs-CRP, regarding pathogen
burden, in a large-scale, community-based study in an Iranian
population.
2. Materials and methods
2.1. Community sampling and baseline examinations
We conducted the present study as part of the Persian Gulf
Healthy Heart Study, which was a prospective population-
based cohort study based on men and women subjects aged
25 years, started in 2003–2004. The Persian Gulf Healthy
Heart Study was designed to determine the risk factors for
cardiovascular diseases among the northern Persian Gulf
population (Bushehr and Hormozghan Provinces) and to
develop community-based interventional projects to change
the lifestyles of the population and to present the rising threat
of cardiovascular diseases in the region. The design of this
study encompasses twomajor components: phase I is a cross-
sectional prevalence study of unhealthy lifestyle and ischemic
heart disease and associated risk factors, and phase II is a
multiple interventional project for reduction of cardiovascular
diseases in the region.
Detailed information about themethods and procedures of
this study is available elsewhere [28]. In an ancillary study to
the Persian Gulf Healthy Heart Study, a total of 1754 (49.2%
males, 50.8% females) subjects were selected through astratified multistage design from major ports of Bushehr
Province (an Iranian province with the greatest boarder with
the Persian Gulf).
All subjects were asked to fast and to present to the survey
center between 7.30 and 9.30 a.m. Blood pressurewas assessed
twice at the right armafter a 15-min rest in the sitting position,
using a standard mercury sphygmomanometer. Height and
weight were measured using a stadiometer. Heavy outer
garments and shoes were removed before measuring height
and weight. Body Mass Index (BMI) was calculated. Waist
circumference was defined at the midway level between the
costal margins and the iliac crests. Hip circumference was
measured at the level of the greater trochanters. A fasting
blood sample was taken, all samples were promptly centri-
fuged, separated and analyses were carried out at the Persian
Gulf Health Research Center on the day of blood collection
using a Selectra 2 autoanalyzer (Vital Scientific, Spankeren,
The Netherlands). Glucose was assayed by enzymatic (glucose
oxidase) colorimetric method using a commercial kit (Pars
Azmun Inc.; Tehran, Iran). Serum total cholesterol and HDL-
cholesterol weremeasured using a cholesterol oxidase phenol
aminoantipyrine and triglycerides using a glycerol-3 phos-
phate oxidase phenol aminoantipyrine enzymatic method.
Serum LDL-cholesterol was calculated using the Friedwald
formula; LDL-cholesterol was not calculated when triglycer-
ides concentration was >400 mg/dl.
2.2. Definitions
The metabolic syndrome was diagnosed with the criteria
indicated by the NCEP-ATP III [4]. According to these criteria,
subjects with the metabolic syndrome are those with any
combination of three or more of the following risk determi-
nants: fasting plasma glucose 6.1 mmol/l, blood pressure
130/85 mmHg or antihypertensive treatment, plasma tri-
glycerides 1.7 mmol/l, plasma HDL cholesterol <1.03 mmol/l
in men and <1.29 mmol/l in women, and waist circumference
>102 cm in men or >88 cm in women.
Smoking was considered to be present when the partici-
pant smoked cigarettes or used a shisha (water pipe) daily.
Respondents were classified as active at the recommended
level if they reported sufficient physical activity of moderate
intensity (30 min per day 5 days per week) or of vigorous
intensity (20 min per day 3 days per week) [29].
The aggregate number of seropositivities to C. pneumoniae,
H. pylori, cytomegalovirus or herpes simplex virus type 1 was
defined as pathogen burden [30].
2.3. Serology
IgG antibodies against C. pneumoniae were measured by a
commercial test kit (DRG Instruments GmbH, Germany). The
principle of the kit was based on an indirect solid-phase
enzyme immunoassay with horseradish peroxidase as a
marker enzyme; the positivity threshold was enzyme immu-
nounits (EIU) >45. Sera were screened for IgG antibodies
against herpes simplex virus type 1, cytomegalovirus and H.
pyloriwith an ELISA (RADIM SpA, Italia), and the samples were
considered positive with IgG values higher than 30 RU/ml for
CMV and H. pylori. Samples with optical density higher than
Table 1 – Clinical characteristics and laboratory values of a random population of the northern Persian Gulf (the study
population) according to the metabolic syndrome (The National Cholesterol Education Program Adult Treatment Panel III).
Normal (n = 841) Metabolic syndrome (n = 913) p value
BMI, kg/m2a 25.6 (5.2) 28.6 (4.9) <0.0001
Systolic blood pressure, mmHg 116.7 (23.3) 134.7 (45.3) <0.0001
Diastolic blood pressure, mmHg 74.8 (21.5) 85.6 (44.7) <0.0001
Total Cholesterol, mg/dl 193.6 (45.5) 217.4 (47.0) <0.0001
HDL-cholesterol, mg/dl 50.7 (45.5) 39.2 (26.7) <0.0001
LDL-cholesterol, mg/dl 120.5 (58.8) 133.0 (48.5) <0.0001
Triglyceride, mg/dl 111.4 (60.7) 225.4 (102.9) <0.0001
Fasting blood sugar, mg/dl 82.3 (16.7) 101.3 (51.9) <0.0001
C-reactive protein, mg/lb 1.4 (3.9) 2.5 (3.6) <0.0001
Smoking, % 28.5 29.6 N.S
Physical inactivity, % 71.8 70.2 N.S
Chlamydia pneumoniae, seropositive, % 16.1 24.6 <0.0001
Helicobacter pylori seropositive, % 26.9 34.8 <0.0001
Cytomegalovirus seropositive, % 44.0 49.2 0.01
Herpes simplex type 1 seropositive, % 40.2 45.9 0.02
Values are mean (SD), except for smoking, physical inactivity and seropositivity to infectious markers.
a BMI indicates body mass index.
b Geometric mean (SD).
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IgG antibodies.
Measurement of CRP by a high-sensitivity CRP assay, CRP
HS ELISA (DRG International, Inc. USA) was done. The
minimum detectable concentration of the CRP HS ELISA assay
was estimated to be 0.1 mg/l. Additionally, the functional
sensitivity was determined to be 0.1 mg/l (as determined with
inter-assay %C.V. <20%).
2.4. Statistical methods
The significance of the difference in the results of any two
groups was determined by chi-square analysis using 2  2
contingency tables for categorical variables and ANOVA for
continuous variables. A two-tailed t-test was used to compare
the mean values across groups.
We found that log transformation of hs-CRP gave a better fit
to a Gaussian distribution. The geometicmean for hs-CRPwas
defined as the arithmetic mean of the log-transformed data
2SD, raised to the power of 10.
Multiple logistic regression analysis was used to ascertain
the associations between log hs-CRP and the metabolic
syndrome. Sex, age, smoking, physical inactivity, hypercho-
lesterolemia and pathogen burden (4, 3, 2 pathogens versus 0–
1 pathogen) were considered as covariates, and the metabolic
syndrome also as the dependent variable in multiple models.
Weexcluded fromstatistical analysis 187 subjectswithhs-CRP
concentrations 10.0 mg/l to exclude possible cases of acute
infections and other occult diseases. p < 0.05 was considered
statistically significant. Statistical analysis was performed
with an IBM computer using the SPSS 9.05 statistical software
package (SPSS Inc., Chicago, IL).
3. Results
Wehave presently analyzed a total of 1754 (49.2%males, 50.8%
females) subjects for the association of the metabolicsyndrome, hs-CRP and infectious burden. Of the studied
subjects, 36.1%was between 25 and 34 years, 29.0%between35
and 44 years, 21.9% between 45 and 54 years, and 12.7%
between 55 and 66 years. Relevant anthropometric informa-
tion including cardiovascular risk factors and biochemical
information in persons with and without the metabolic
syndrome are given in Table 1.
The prevalence of consumption of antihypertensive,
hypolipidemic and anti-diabetic drugs were 6.5%, 3.5% and
3.8%, respectively.
A total of 913 (52.1%) of the subjects (56.30% of males and
48.0% of females; p < 0.0001) had the metabolic syndrome
(NCEP-ATP III criteria).
The geometric mean of CRP was 1.94 mg/l (1.03 SE) in the
studied population. Quartiles (Q) for the population distribu-
tion for CRP were as follows: Q1, 0.04–0.80 mg/l; Q2, 0.81–
1.70 mg/l; Q3, 1.71–4.50 mg/l; and Q4, 4.51–338.00 mg/l. CRP
levels were higher in women (geometric mean = 2.29 mg/l)
than men (geometric mean = 1.62 mg/l), ( p < 0.0001). The
subjects with the metabolic syndrome had a higher geometric
mean of CRP levels than the normal persons [2.51 (SE 1.04)
versus 1.46 (1.05) mg/l, respectively; p < 0.0001)] (Table 1).
Age-adjusted odds ratio (95%, CI) between the metabolic
syndrome and hs-CRP levels was 1.48 (1.12–1.95), p = 0.005 for
men and 2.41 (1.85–3.14), p < 0.0001 for women.
The prevalence of IgG antibodies against CMV, HSV, C.
pneumoniae and H. pylori were higher in subjects with the
metabolic syndrome than healthy persons (Table 1). The
prevalence of the number of pathogens (0–1, 2, 3, and 4) was
6.3%, 26.3%, 42.9% and 23.9%, respectively. There was an
increased trend of prevalence of themetabolic syndromewith
increasing number of pathogens (4.0%, 22.6%, 43.4% and 29.7%
for 1, 2, 3, and 4 pathogens, respectively; p for trend < 0.0001).
A linear relationship between an increase in the number of
pathogens and CRP concentrations was also observed
( p = 0.003).
The individual components of the metabolic syndrome as
well as the concentration of the hs-CRP were analyzed (data
Table 2 – Multivariately adjusted odds ratios (OR) and 95% confidence intervals (CI) relating hs-CRP and the metabolic
syndrome among the study populationa.
Independent variables Two pathogen Three pathogen Four pathogen
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Hypercholesterolemia (240 vs <240 mg/dl) 0.90 0.53–1.51 0.69 1.82 1.21–2.74 0.004 1.17 0.70–1.96 0.54
log CRP, mg/l 2.06 1.32–3.21 0.001 1.75 1.26–2.42 0.001 2.12 1.46–3.08 <0.0001
Smoking (yes vs no) 0.54 0.33–0.88 0.01 0.76 0.52–1.11 0.16 0.85 0.53–1.37 0.51
Physical inactivity (yes vs no) 1.39 0.89–2.18 0.14 1.47 1.04–2.10 0.02 0.96 0.61–1.51 0.88
Sex (male vs female) 2.07 1.37–3.12 <0.0001 1.69 1.22–2.35 0.002 2.28 1.49–3.47 <0.0001
Age groups (years)b
35–44 1.72 1.06–2.80 0.02 1.46 0.99–2.16 0.05 1.91 1.16–3.16 0.01
45–54 2.42 1.33–4.40 0.004 2.50 1.58–3.94 <0.0001 2.46 1.37–4.42 0.003
55–66 3.23 1.51–6.92 0.003 3.24 1.74–6.01 <0.0001 2.19 1.07–4.48 0.3
Pathogen burdenc 1.69 1.00–2.85 0.04 1.95 1.18–3.20 0.008 3.05 1.80–5.16 <0.0001
a log CRP considered as a single entity, sex, age, hypercholesterolemia, smoking, physical inactivity and pathogen burden as covariates, and
the metabolic syndrome (NCEP ATP-III) as the dependent variable.
b The risks are relative to age group 24–34.
c The risks are relative to 0–1 pathogen.
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higher in all components of the metabolic syndrome
(p < 0.0001). A linear relationship between an increase in
the number of metabolic syndrome components and CRP
concentrations was observed (Fig. 1); geometric mean hs-CRP
levels for thosewith 1 versus 5 characteristics of themetabolic
syndrome were 1.18 and 4.22 mg/l, respectively (trend,
p < 0.0001). Similar results were obtained when subjects were
classified according to number of pathogens. Geometric mean
of hsCRP levels for those with 1 versus 5 characteristics of the
metabolic syndrome were 1.05 and 3.34 mg/l (trend, p = 0.006),
1.24 and 3.09 mg/l (trend, p < 0.0001), 1.32 and 4.66 mg/l (trend,
p < 0.0001), 1.13 and 4.19 mg/l (trend, p < 0.0001) in those with
0–1, 2, 3 and 4 pathogens, respectively.
In multiple logistic regression analysis log hs-CRP, showed
a significant association with the metabolic syndromeFig. 1 – Distribution of log C-reactive protein (hs-CRP) levels
according to the number of the metabolic syndrome (NCEP
ATP-III) components in the study population. Data
presented as means (SE).[OR = 1.96, CI (1.59–2.43), p < 0.0001] after adjusting for sex,
age, hypercholesterolemia, smoking and physical inactivity.
Serum hs-CRP levels also showed a significant association
with the metabolic syndrome [OR = 1.90, CI (1.56–2.31),
p < 0.0001] after adjusting for age, sex and subclinical infection
with CMV, HSV, C. pneumoniae and H. pylori.
In multiple logistic regression models with the metabolic
syndrome as the dependent variable (Table 2), log CRP and
cardiovascular risk factors as independent variables, hs-CRP
showed significant associations with the metabolic syndrome
after controlling for infectious burden divided into 2, 3 and 4
pathogens [OR = 2.06, CI (1.32–3.21), p = 0.001; OR = 1.75, CI
(1.26–2.42), p = 0. 001; OR = 2.12, CI (1.46–3.08), p < 0.0001],
respectively.
4. Discussion
In this large-scale, population-based study, hs-CRP levelswere
associated with the metabolic syndrome. This association
remained in the study population after adjustment for burden
of viral and bacterial pathogens that had been identified as
important factors influencing, inflammation, human coronary
aswell as carotid atherosclerosis, and themetabolic syndrome
[24,24,27,31].
The concept of infectious burden is interesting; it is defined
as the number of seropositivity to infectious pathogen to
which an individual has been exposed [30]. The impact of viral
and bacterial infectious burden on long-term prognosis in
patients with coronary artery disease and essential hyperten-
sion had been shown [31,32]. There is little information about
the impact of pathogen burden on the development of chronic
insulin resistance or the metabolic syndrome [24–26]. These
studies had controversial results about the association
between pathogen burden and the metabolic syndrome or
insulin resistance. A significant association betweenburden of
infection, especially with enteroviruses and C. pneumoniae
seropositivity, and insulin sensitivitywas described in healthy
middle-aged men [24]. But Howard et al. reported no relation-
ship between pathogen burden and inflammation, and insulin
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in a population with high burden of subclinical infection [26].
Recently, in the first report of our population-based study,
we showed that themetabolic syndromehada significantwith
prior infection with HSV-1, CMV, H. pylori and C. pneumoniae
[27]. Thus, it was hypothesized that these viral and bacterial
pathogens induce production of proinflammatory cytokines,
such as TNF-alpha and IL-6 which are leading to chronic
subclinical inflammation, insulin resistance and the meta-
bolic syndrome.
In the present study, we therefore adjusted for burden of
the latter infectious agents, which could confound association
of the metabolic syndrome and hs-CRP, in logistic regression
models. We observed that the association between CRP and
the metabolic syndrome persisted after controlling for 2, 3,
and 4 numbers of organisms that had been previously
associated with coronary artery disease.
Theassociationof infectiousburdenandmetabolicabnorm-
alities, with the degree of inflammation was compared in 569
patientswith coronary artery disease [25]. They concluded that
comparedwith infectious burden,metabolic abnormalities had
amoreprominent associationwith the degreeof inflammation,
severity of coronary atherosclerosis and the major cardiovas-
cular events [25]. Our findings are in agreement with their
conclusions and suggest hs-CRP is associated with the meta-
bolic syndrome, independent to the number of infectious
pathogens which an individual has been exposed.
Multiple cross-sectional and prospective epidemiological
studies showed an association between hs-CRP and the
metabolic syndrome and its components [11–20]. However,
the mechanisms responsible for the low-grade up-regulation
of CRP production that predicts development of the metabolic
abnormalities in general population are not clearly under-
stood. It has been hypothesized that increased secretion of IL-
6 and proinflammatory cytokines from expanded adipose
tissue mass up-regulates the production of CRP by the liver.
This in turn can induce insulin resistance and results in
accentuation of other metabolic abnormalities that constitute
the metabolic syndrome [15,33].
Genetics also influences relationship of CRP, insulin
resistance and the metabolic syndrome. Substantial genetic
effects in CRP variation are present outside the CRP gene itself.
A genome-wide association study among 6345 apparently
healthy women in the Women’s Genome Health Study
revealed that most of the common genetic polymorphism
that contributes to CRP level was closely related to genetic
pathways known to have an impact on metabolic syndrome,
insulin resistance, beta cell function, weight homeostasis,
and/or premature atherosclerosis [34]. These genetic findings
linking chronic, low-grade inflammation to loci known
functionally to relate to metabolic abnormalities to be of
considerable interest given epidemiologic data linking hs-CRP
levels to the metabolic syndrome and its components. These
genetic data support a potential causal role for CRP itself.
Our study confirmed that levels of hs-CRP were positively
correlated with the number of components of the metabolic
syndrome according to NCEP definitions.
Several studies have reported a relationship between
components of the metabolic syndrome, according to the
ATP III definition, and hs-CRP [16,17,20,35,36].Intravascular kinetics of CRP, using stable isotopes,
revealed that the CRP production rate, as the main determi-
nant of CRP concentrations, had significant association with
features of the metabolic syndrome as well as with adipose
tissue-derived cytokines such as IL-6 and adiponectin [37]. In
Finnish population-based study, decreased levels of adipo-
nectin and increased levels of hs-CRP and IL-Ira were tightly
associated with the components of the metabolic syndrome
[36]. These data could explain our finding of a gradual increase
in log CRP levels with increasing numbers of the metabolic
syndrome components.
Fernandez-Real et al. suggested that inflammation is
behind the link between pathogen burden and insulin
resistance because significant relationship between the
number of infectious pathogens and insulin sensitivity did
not persist after controlling for CRP [24]. But significant
association of pathogen burden and the metabolic syndrome
persisted in our regression models when CRP levels were
simultaneously entered. This finding suggests that inflamma-
tion does not significantly influence the relationship between
the metabolic syndrome and pathogen burden and both
inflammation and pathogen burden are independently asso-
ciated with the metabolic syndrome.
In the present study, women had higher hs-CRP levels than
men. The metabolic syndrome also showed a higher age-
adjusted association with elevated hs-CRP levels in women
than men. However, the prevalence of the metabolic syn-
drome was significantly higher in men than in women. This
discrepancy shows that the relationship of hs-CRP and the
metabolic syndrome is not a simple cause and effect and
multiple factors should be considered in a complex system to
explain the ethiopathogenesis of the metabolic syndrome.
Blood levels of CRP and IL-6 are also associated with higher
risk of Alzheimer disease and cognitive decline during aging
[38]. Recent evidences also suggest that the metabolic
syndrome is a risk factor for accelerated cognitive aging,
especially among those with high levels of inflammation
[39,40]. To reduce the potential adverse effects of the
inflammation that accompanies the metabolic syndrome
and the cognitive decline, those with this syndrome should
avoid excessive energy intake, and increase their daily
physical activities.
We acknowledge study limitations. In the present studywe
used NCEP-ATP III definition for the metabolic syndrome.
Although this definition is most often used, other definitions
for themetabolic syndrome do exist. Another limitation of our
study includes the lack of measurement of insulin resistance
from fasting glucose and insulin concentrations using the
HOMAmethod. Another limitation is thatweused a single CRP
measurement that may not accurately reflect long-term
inflammation status. We conducted our study in a large
random population and used seropositivity as a marker for
infections; however, it has the advantage of clinical applic-
ability, but the assessment of infection status based on
serology without further clinical or laboratory characteriza-
tion is subject to diagnostic inaccuracies, especially if
seropositivity is common because of the widespread distribu-
tion of the incriminated microorganism. In our study, the
presence of seropositivity to other confounding viral or
bacterial pathogens cannot be ruled out.
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inferring causality from the results. Future research should
include longitudinal studies of the metabolic syndrome,
proinflammatory biomarkers and a comprehensive survey
for chronic viral and bacterial infections to determine
temporal sequence of any relationship.
In conclusion, in a large representative sample of Iranian
population, we showed a strong association between inflam-
mation and the metabolic syndrome, independent to burden
of common viral and bacterial infections pathogens that had
been previously associated with human coronary as well as
carotid atherosclerosis. Although it is difficult to conclude if
low-grade inflammation induces insulin resistance and the
metabolic syndromeor is a consequence, strong association of
hs-CRP levels and the metabolic syndrome independently to
chronic infections promises to be exciting and groundbreak-
ing. The effective administration of anti-nflammatory agents,
in the treatment of insulin resistance and atherosclerosis is
only the beginning of a new approach in the management of
the metabolic syndrome.
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